{"id":"inactive-poliovirus-vaccine","safety":{"commonSideEffects":[{"rate":"10–30%","effect":"Injection site pain, erythema, or swelling"},{"rate":"1–5%","effect":"Fever"},{"rate":"5–15%","effect":"Myalgia or fatigue"},{"rate":"1–5%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses, leading to the production of neutralizing antibodies against poliovirus types 1, 2, and 3. This provides protection against poliomyelitis infection through immunological memory without the risk of vaccine-derived poliovirus that can occur with live attenuated vaccines.","oneSentence":"Inactive Poliovirus Vaccine stimulates the immune system to produce antibodies against all three serotypes of poliovirus without causing disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:23.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3"}]},"trialDetails":[{"nctId":"NCT04693286","phase":"PHASE2","title":"Clinical Trial of Novel OPV2 Vaccine","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2020-09-21","conditions":"Poliomyelitis","enrollment":330},{"nctId":"NCT02005536","phase":"PHASE4","title":"Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-12","conditions":"Poliomyelitis, Polio","enrollment":60},{"nctId":"NCT01389687","phase":"PHASE3","title":"Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07","conditions":"Poliomyelitis, Polio","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SP059"],"phase":"phase_3","status":"active","brandName":"Inactive Poliovirus Vaccine","genericName":"Inactive Poliovirus Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Inactive Poliovirus Vaccine stimulates the immune system to produce antibodies against all three serotypes of poliovirus without causing disease. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}